首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Breast Cancer Research

Breast Cancer Research杂志,由BioMed Central出版,于1999年创刊,Bimonthly,出版语言English,ISSN:1465-542X,E-ISSN:1465-542X。

投稿咨询
Breast Cancer Research
Breast Cancer Research
Breast Cancer Research
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
2区
影响因子
6.2
CiteScore
8.1
期刊收录
SCI、SCIE

Breast Cancer Research(中文译名:《乳腺癌研究》),ISSN:1465-542X,EISSN:1465-542X,是BioMed Central出版的国际性学术期刊,创刊于1999年,以Bimonthly形式稳定发行,2026年总发文量约236篇。该刊采用OA开放访问,学科归属为ONCOLOGY。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达6.2,2025年期刊CiteScore为8.1,2025年期刊自引率约3.2%,在中科院期刊分区体系中位列医学大类2区,在所属学科领域具备高学术影响力与国际认可度。Breast Cancer Research长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期一般,3-8周,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USAEngland、Italy、Sweden、Canada、GERMANY (FED REP GER)、Australia等为核心发文国家与地区;UNIVERSITY OF LONDONUNIVERSITY OF TEXAS SYSTEM、HARVARD UNIVERSITY、KAROLINSKA INSTITUTET、UNICANCER、UNIVERSITY OF CALIFORNIA SYSTEM、UNIVERSITY OF MELBOURNE等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学
2区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学
2区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学
2区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 60 / 333

82.1

学科:ONCOLOGY SCIE Q1 59 / 333

82.43

2023-2024年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 49 / 322

84.9

学科:ONCOLOGY SCIE Q1 47 / 322

85.56


中国学者近期发文

1
AI-enhanced precision: boosting pathologist confidence in HER2 ultra-low diagnosis through intelligent re-screenin

Author:Wang, Xin-ping; Han, Ying; Yao, Min; Gao, Hong-Wen; Sun, Ping-Li

Journal: BREAST CANCER RESEARCH. 2026; Vol. 28, Issue 1, pp. -. DOI: 10.1186/s13058-026-02261-4

2
TLScope: a deep learning framework for quantifying tertiary lymphoid structures from H&E images reveals prognostic heterogeneity across breast cancer subtype

Author:Wang, Ruyuan; Liu, Sunyan; Zhao, Yuxi; Su, Yuhang; Peng, Qiyue; Zhu, Linsha; Zheng, Yiqiu; Xin, Ying; Li, Jiasu; Du, Yaying; Li, Ke; Li, Xingrui

Journal: BREAST CANCER RESEARCH. 2026; Vol. 28, Issue 1, pp. -. DOI: 10.1186/s13058-026-02241-8

3
CD19+Ki67+B cells regulated by NAMPT as key modulators in triple-negative breast cancer with brain metastasi

Author:Zhou, Qiyi; Zhu, Zhimin; Zhao, Yuxin; Jing, Di; Zhang, Liyuan

Journal: BREAST CANCER RESEARCH. 2026; Vol. 28, Issue 1, pp. -. DOI: 10.1186/s13058-026-02251-6

4
Chidamide combined with fulvestrant in the treatment of HR-positive, HER2-negative advanced breast cancer after failure of previous endocrine therapy: a single-arm, single-center, phase 2 stud

Author:Zou, La; Tang, Xianjun; Deng, Pan; Liu, Yijing; Yang, Ti; Tan, Xin; Yang, Lu; Li, Wei; Zeng, Xiaohua

Journal: BREAST CANCER RESEARCH. 2026; Vol. 28, Issue 1, pp. -. DOI: 10.1186/s13058-026-02254-3

5
FBR-NDs: a ferroptosis-inducing nanocomplex for targeted breast cancer therapy via immune modulation and redox-responsive drug deliver

Author:Chen, Jinjin; Ma, Liang; Yin, Ming; Sun, Jian; Sun, Yunhao

Journal: BREAST CANCER RESEARCH. 2026; Vol. 28, Issue 1, pp. -. DOI: 10.1186/s13058-026-02247-2

6
Mechanism of IL-4 mediated RPL19 promoting malignant progression in HER2 positive breast cance

Author:Zhang, Nana; Zhang, Jian; Shao, Junchao; Huang, Zhenfeng; Zhang, Jinxing; Wang, Hao; Lv, Liangshuang; Shen, Zibo; Zhang, Peng; Liu, Bing; Zhang, Guoqiang; Shan, Ming

Journal: BREAST CANCER RESEARCH. 2026; Vol. 28, Issue 1, pp. -. DOI: 10.1186/s13058-026-02240-9

7
Vascular abnormalization confers tumor resistance to antiangiogenic therapy via downregulating angiostatic factor

Author:Mao, Xunyuan; Cao, Xiangyu; Qian, Long; Gao, Meng; Zhang, Naidong; Huang, Mengmeng; Fan, Peng; Qi, Ziwei; Liu, Tingkun; Zhang, Hongjie; Huang, Yuhui

Journal: BREAST CANCER RESEARCH. 2026; Vol. 28, Issue 1, pp. -. DOI: 10.1186/s13058-026-02229-4

8
O-GlcNAcylation regulates the DNA damage repair function of MND1 in breast cance

Author:Zhai, Zhen; Wu, Jinpeng; Wei, Yumeng; Song, Ping; Wang, Meng; Lin, Shuai; Ma, Xiaobin; Lu, Yurong; Yang, Pengbo; Tan, Zengqi; Guan, Feng; Li, Xiang; Kang, Huafeng

Journal: BREAST CANCER RESEARCH. 2026; Vol. 28, Issue 1, pp. -. DOI: 10.1186/s13058-026-02233-8

9
Tumor heterogeneity index from DCE-MRI for AKT-inhibition responder identification and reveals hot immune microenvironment for patients with breast cancer: a multi-omics analysis of I-SPY2 tria

Author:Teng, Xinzhi; Zhang, Jiang; Lai, Qingpei; Li, Wen; Fan, Xinyu; Zhang, Xinyu; Huang, Yu-hua; Wang, Jiahuan; Liu, Chenyang; Ren, Ge; Zaidi, Habib; Lee, Elaine Yuen Phin; El Helali, Aya; Zhao, Lina; Sun, Defeng; Cai, Jing

Journal: BREAST CANCER RESEARCH. 2026; Vol. 28, Issue 1, pp. -. DOI: 10.1186/s13058-026-02219-6

10
Targeting glucocorticoid receptor to enhance immunotherapy response in triple negative breast cance

Author:Yang, Lei; Chen, Zhenzhou; Chen, Yajun; Yang, Jian; Liu, Shengchun; Deng, Kun; Xu, Jianping; Cui, Ming; Fu, Zhongxue

Journal: BREAST CANCER RESEARCH. 2026; Vol. 28, Issue 1, pp. -. DOI: 10.1186/s13058-026-02230-x


在线咨询

Breast Cancer Research

国际简称:BREAST CANCER RES参考译名:乳腺癌研究

年发文量:236 CiteScore:8.1 是否预警:否 Gold OA文章占比:100.00% 研究类文章占比:97.46%

杂志社联系方式:CAMPUS, 4 CRINAN ST, LONDON, ENGLAND, N1 9XW

Breast Cancer Research